Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

Medical Microbiology and Immunology

Volumn 202, Issue 2, 2013, Pages 95-104

  Prabowo, Satria A ^a   Gröschel, Matthias I ^a   Schmidt, Ed D L ^b   Skrahina, Alena ^c   Mihaescu, Traian ^d   Hastürk, Serap ^e   Mitrofanov, Rotislav ^f   Pimkina, Edita ^g   Visontai, Ildikó ^h   De Jong, Bouke ⁱ   Stanford, John L ^j   Cardona, Père Joan ^k   Kaufmann, Stefan H E ^l   Van Der Werf, Tjip S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Republican Scientific and Practical Center for Pulmonology and Tuberculosis   (Belarus)

^d Clinical Hospital of Pneumology   (Romania)

^e Yedekule Hospital Chest Clinic   (Turkey)

^f Department of Urogenital   (Russian Federation)

^g VILNIUS UNIVERSITY   (Lithuania)

^h NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

ⁱ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^l MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

more..

Author keywords

Drug resistant; Immunology; Immunotherapy; Persistent bacteria; Review; Therapeutic vaccine; Tuberculosis

Indexed keywords

BCG VACCINE; BEDAQUILINE; DELAMANID; EARLY SECRETORY ANTIGENIC TARGET 6; GELATINASE B; LINEZOLID; SUTEZOLID;

EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; UPREGULATION;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84879670662     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-012-0278-6     Document Type: Review

References (130)

1. Keshavjee S, Farmer PE (2012) Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 367(10):931-936
2. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328(8):521-526
3. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326(23):1514-1521
4. World Health Organization (1994) Tuberculosis: a global emergency. WHO, Geneva
5. Raviglione M, Marais B, Floyd K et al (2012) Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379(9829):1902-1913
6. Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, Venkatesan P, Prabhakar R, Datta M (2000) Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 4(9):839-844
7. World Health Organization (2011) Global tuberculosis control. WHO, Geneva
8. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, Weil D, Raviglione M (2010) MDR tuberculosis - critical steps for prevention and control. N Engl J Med 363(11):1050-1058
9. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich V, Zignol M (2012) Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39(6):1425-1431
10. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR TB) - Global Report on Surveillance and Response 2010. WHO, Geneva
11. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547):1575-1580
12. Zhao Y, Xu S, Wang L et al (2012) National survey of drug-resistant tuberculosis in China. N Engl J Med 366(23):2161-2170
13. Liang L, Wu Q, Gao L et al (2012) Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax 67(7):632-638
14. Olson EN (2004) Undermining the endothelium by ablation of MAPK-MEF2 signaling. J Clin Invest 113(8):1110-1112
15. Chaisson RE, Nuermberger EL (2012) Confronting multidrug-resistant tuberculosis. N Engl J Med 366(23):2223-2224
16. Ahuja SD, Ashkin D, Avendano M et al (2012) Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 9(8):e1001300
17. Diel R, Rutz S, Castell S, Schaberg T (2012) Cost of illness of tuberculosis in Germany. Eur Respir J 40(1):143-151
18. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9(3):153-161
19. Yew WW, Lange C, Leung CC (2011) Treatment of tuberculosis: update 2010. Eur Respir J 37(2):441-462
20. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, Skenders G, Holtz TH (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 36(3):584-593
21. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM (2007) First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill Eur Commun Dis Bull 12(5):E070517.1
22. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi AH, Hoffner SE (2009) Emergence of new forms of totally drug-resistant Tuberculosis Bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136(2):420-425
23. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54(4):579-581
24. Chang KC, Leung CC, Grosset J, Yew WW (2011) Treatment of tuberculosis and optimal dosing schedules. Thorax 66(11):997-1007
25. Faustini A (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61(2):158-163
26. Pasipanodya JG, Srivastava S, Gumbo T (2012) Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55(2):169-177
27. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M (2012) The Immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 205(suppl 2):S301-S315
28. Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S (2012) Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 217(3):363-374
29. van Altena R, Duggirala S, Gröschel MIP, van der Werf TS (2011) Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des 17(27):2853-2862
30. Kleinnijenhuis J, Oosting M, Joosten LAB, Netea MG, van Crevel R (2011) Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011:1-12
31. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y (2010) The immunology of tuberculosis: from bench to bedside. Respirology 15(3):433-450
32. Fabri M, Stenger S, Shin D-M et al (2011) Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 3(104):104ra102
33. Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG (1998) Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 160(3):1290-1296
34. Liu PT, Modlin RL (2008) Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 20(4):371-376
35. Welin A, Lerm M (2012) Inside or outside the phagosome? The controversy of the intracellular localization of Mycobacterium tuberculosis. Tuberc (Edinb) 92(2):113-120
36. Rohde KH, Abramovitch RB, Russell DG (2007) Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2(5):352-364
37. Russell DG (2001) Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2(8):569-577
38. Melo RCN, Dvorak AM (2012) Lipid body-phagosome interaction in macrophages during infectious diseases: host defense or pathogen survival strategy? PLoS Pathog 8(7):e1002729
39. Peyron P, Vaubourgeix J, Poquet Y et al (2008) Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4(11):e1000204
40. Pandey AK, Sassetti CM (2008) Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA 105(11):4376-4380
41. Colombo MI, Beron W, Stahl PD (1997) Calmodulin regulates endosome fusion. J Biol Chem 272(12):7707-7712
42. Maniak M, Rauchenberger R, Albrecht R, Murphy J, Gerisch G (1995) Coronin involved in phagocytosis: dynamics of particle-induced relocalization visualized by a green fluorescent protein Tag. Cell 83(6):915-924
43. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178(6):2249-2254
44. Kaufmann SHE (2010) Novel tuberculosis vaccination strategies based on understanding the immune response. J Int Med 267(4):337-353
45. Herbst S, Schaible UE, Schneider BE (2011) Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS ONE 6(5):e19105
46. Ní Cheallaigh C, Keane J, Lavelle EC, Hope JC, Harris J (2011) Autophagy in the immune response to tuberculosis: clinical perspectives. Clin Exp Immunol 164(3):291-300
47. Hanekom WA, Dockrell HM, Ottenhoff THM, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ (2008) Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5(7):e145
48. Rook GAW, Hernández-Pando R, Dheda K, Teng Seah G (2004) IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25(9):483-488
49. VanHeyningen TK, Collins HL, Russell DG (2001) IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses. J Immunol 158(1):330-337
50. Hett EC, Rubin EJ (2008) Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 72(1):126-156
51. Cardona P-J (2006) RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberc (Edinb) 86(3-4):273-289
52. Gengenbacher M, Kaufmann SHE (2012) Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 36(3):514-532
53. Zhang Y, Yew WW, Barer MR (2012) Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 56(5):2223-2230
54. Cardona P-J (2010) Revisiting the natural history of tuberculosis. Arch Immunol Ther Exp (Warsz) 58(1):7-14
55. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845-855
56. Locht C, Rouanet C, Hougardy J-M, Mascart F (2007) How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis. Expert Opin Biol Ther 7(11):1665-1677
57. Neyrolles O, Hernández-Pando R, Pietri-Rouxel F et al (2006) Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS ONE 1(1):e43
58. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, Rook GA, Bjune G (2000) Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356(9248):2133-2138
59. Barrios-Payan J, Saqui-Salces M, Jeyanathan M, Alcantara-Vazquez A, Castanon-Arreola M, Rook G, Hernandez-Pando R (2012) Extrapulmonary locations of Mycobacterium tuberculosis DNA during latent infection. J Infect Dis 206(8):1194-1205
60. Clay H, Volkman HE, Ramakrishnan L (2008) Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29(2):283-294
61. Lin PL, Myers A, Smith L et al (2010) Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62(2):340-350
62. Iliopoulos A, Psathakis K, Aslanidis S, Skagias L, Sfikakis PP (2006) Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int J Tuberc Lung Dis 10(5):588-590
63. Bru A, Cardona P-J (2010) Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice. PLoS ONE 5(9):e12985
64. Cardona P-J, Ivanyi J (2011) The secret trumps, impelling the pathogenicity of tubercle bacilli. Enferm Infecc Microbiol Clin 29(Suppl 1):14-19
65. Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12(5):352-366
66. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L (2010) Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327(5964):466-469
67. Black GF, Thiel BA, Ota MO et al (2009) Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 16(8):1203-1212
68. Schnappinger D, Schoolnik GK, Ehrt S (2006) Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another. Microb Infect 8(4):1132-1140
69. Garton NJ, Waddell SJ, Sherratt AL et al (2008) Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5(4):e75
70. Chegou NN, Black GF, Loxton AG et al (2012) Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis 12(1):10
71. Chegou NN, Essone PN, Loxton AG et al (2012) Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS ONE 7(6):e38501
72. Boon C, Dick T (2010) How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later. Futur Microbiol 7(4):513-518
73. Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139-163
74. Keren I, Minami S, Rubin E, Lewis K (2011) Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. mBio 2(3):e00100-e00111
75. Manganelli R, Voskuil MI, Schoolnik GK, Smith I (2001) The Mycobacterium tuberculosis ECF sigma factor sigmaE: role in global gene expression and survival in macrophages. Mol Microbiol 41(2):423-437
76. Aagaard C, Hoang T, Dietrich J, Cardona P-J, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17(2):189-194
77. Mitchison D, Davies G (2012) The chemotherapy of tuberculosis: past, present and future [State of the art]. Int J Tuberc Lung Dis 16(6):724-732
78. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J (2012) New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 205(suppl 2):S241-S249
79. Gler MT, Skripconoka V, Sanchez-Garavito E et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366(23):2151-2160
80. Diacon AH, Donald PR, Pym A et al (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56(6):3271-3276
81. Alffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, van Soolingen D (2011) Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 55(3):1287-1289
82. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL (2012) Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56(6):3114-3120
83. Pranger AD, Kosterink JGW, van Altena R, Aarnoutse RE, van der Werf TS, Uges DRA, Alffenaar J-WC (2011) Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 33(3):350-354
84. Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DRA, Kosterink JGW, van der Werf TS, Alffenaar JWC (2011) Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 38(4):888-894
85. Alffenaar J-WC, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AMA, van Soolingen D, Kosterink JGW, Uges DRA, van der Werf TS (2010) Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 49(8):559-565
86. Alffenaar J-WC, Kosterink JGW, van Altena R, van der Werf TS, Uges DRA, Proost JH (2010) Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32(1):97-101
87. Alffenaar JWC, van Altena R, Bökkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, van der Werf TS (2009) Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 49(7):1080-1082
88. Srivastava S, Pasipanodya JG, Gumbo T (2012) Reply to Alffenaar. J Infect Dis 205(11):1766
89. McShane H (2011) Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 366(1579):2782-2789
90. Kaufmann SH, Hussey G, Lambert P-H (2010) New vaccines for tuberculosis. Lancet 375(9731):2110-2119
91. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M (2011) The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 8(3):e1001012
92. Ottenhoff THM, Kaufmann SHE (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8(5):e1002607-e1002612
93. Maleszewska M, Moonen J-RAJ, Huijkman N, van de Sluis B, Krenning G, Harmsen MC (2012) IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology. doi: 10.1016/j.imbio.2012.05.026
94. Beresford B, Sadoff JC (2010) Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 50(s3):S178-S183
95. Krenning G, Zeisberg EM, Kalluri R (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225(3):631-637
96. Kaufmann SHE (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33(4):567-577
97. World Health Organization (2011) Global Plan to Stop TB. WHO, Geneva
98. Skeiky YAW, Alderson MR, Ovendale PJ et al (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172(12):7618-7628
99. Grange JM, Brunet LR, Rieder HL (2011) Immune protection against tuberculosis - when is immunotherapy preferable to vaccination? Tuberc (Edinb) 91(2):179-185
100. Suthar AB, Lawn SD, del Amo J et al (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9(7):e1001270
101. von Reyn CF, Mtei L, Arbeit RD et al (2010) Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5):675-685
102. Stanford JL, Grange JM (1994) The promise of immunotherapy for tuberculosis. Respir Med 88(1):3-7
103. Yang X-Y, Chen Q-F, Li Y-P, Wu S-M (2011) Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS ONE 6(9):e23826
104. ®. Vaccine 28(4):1106-1116
105. Hawkridge T, Mahomed H (2011) Prospects for a new, safer and more effective TB vaccine. Paediatr Respir Rev 12(1):46-51
106. Arjanova VO, Prihoda DN, Yurchenko VL, Sokolenko NI, Frolov MV (2010) Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C Co-infected with HIV and Mycobacterium tuberculosis. J Vaccines Vaccin 01(01):1-5
107. Butov DA, Pashkov YN, Stepanenko AL, Choporova AI, Butova TS, Batdelger D, Jirathitikal V, Bourinbaiar AS, Zaitzeva SI (2011) Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines 9(1):3
108. Koch R (1891) A further communication on a remedy for tuberculosis. BMJ 1(1568):125-127
109. Gradmann C (2001) Robert Koch and the pressures of scientific research: tuberculosis and tuberculin. Med Hist 45(1):1-32
110. Die Atiologie der Tuberculose. Facsimile of the original contribution by Robert Koch in "Berliner Klinische Wochenschrift" 10 April 1882
111. British Medical Research Council (1972) Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1(7760):1079-1085
112. Grange JM (1997) Immunotherapy: a new strategy for tuberculosis control? Respir Med 91(1):1-4
113. Stanford J, Stanford C, Stansby G, Bottasso O, Bahr G, Grange J (2009) The common mycobacterial antigens and their importance in the treatment of disease. Curr Pharm Des 15(11):1248-1260
114. Camporota L, Corkhill A, Long H et al (2003) The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 21(2):287-293
115. Fontanella GH, Pascutti MF, Daurelio L, Perez AR, Nocito AL, Wojdyla D, Bottasso O, Revelli SS, Stanford JL (2007) Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental Actinomycetales. Vaccine 25(17):3492-3500
116. Stansby G, Chan YC, Berwanger CS, Shurey S, Rook GAW, Stanford JL (2002) Prevention of experimental myointimal hyperplasia by immunomodulation. Eur J Vasc Endovasc Surg 23(1):23-28
117. Abbot NC, Beck JS, Feval F, Weiss F, Mobayen MH, Ghazi Saidi K, Dowlati Y, Velayati AA, Stanford JL (2002) Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg 24(3):202-208
118. Stanford JL, Stanford CA, O'Brien MER, Grange JM (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44(2):224-227
119. Marro A, Pirles M, Schiaffino L, Bin L, Dávila H, Bottasso OA, McIntyre G, Ripley PR, Stanford CA, Stanford JL (2011) Successful immunotherapy of canine flea allergy with injected Actinomycetales preparations. Immunotherapy 3(8):971-978
120. Ramu G, Prema GD, Balakrishnan S, Shanker Narayan NP, Stanford JL (1990) A preliminary report on the immunotherapy of psoriasis. Indian Med Gazette 124:381-382
121. Lehrer A, Bressanelli A, Wachsmann V, Bottasso O, Bay ML, Singh M, Stanford C, Stanford J (1998) Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 21(1):71-77
122. Gil O, Guirado E, Gordillo S, Díaz J, Tapia G, Vilaplana C, Ariza A, Ausina V, Cardona P-J (2006) Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type. Microb Infect 8(3):628-636
123. Uhlin M, Andersson J, Zumla A, Maeurer M (2012) Adjunct immunotherapies for tuberculosis. J Infect Dis 205(suppl 2):S325-S334
124. Van Deun A, Maug AKJ, Hossain A, Gumusboga M, de Jong BC (2012) Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis. Int J Tuberc Lung Dis 16(9):1174-1179
125. Hamid Salim A, Aung K, Hossain MA, Van Deun A (2006) Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 10(11):1248-1254
126. Warmelink I, ten Hacken NH, van der Werf TS, van Altena R (2010) Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 105(03):400-408
127. Warmelink I, van Altena R, ten Hacken N, van der Werf T, van der Veer E (2011) Nutritional status and vitamin D3 during antimicrobial treatment. Lancet 377(9775):1407-1408
128. Campbell GR, Spector SA (2012) Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 8(5):e1002689
129. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM (2012) Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 12(2):157-166
130. Iddriss A, Padayatchi N, Reddy D, Reddi A (2012) Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa. Ann Thorac Surg 94(2):381-386